McCune-Albright syndrome
Learn about McCune-Albright syndrome, its reported features, relevant specialists, and questions to discuss at a medical consultation.
Also known as: Albright syndrome; Albright's disease; Albright's disease of bone; Albright's syndrome; Albright's syndrome with precocious puberty; Albright-McCune-Sternberg syndrome and 7 more
Albright-Sternberg syndrome; Fibrous dysplasia with pigmentary skin changes and precocious puberty; MAS; Osteitis fibrosa disseminata; PFD; POFD; Polyostotic fibrous dysplasia
The sources compiled here do not cover: diagnosis, treatment, prevention, prognosis. Ask the treating doctor about these.
What it is, symptoms and effects
From: MedlinePlus Genetics, National Library of Medicine
McCune-Albright syndrome is a disorder that affects the bones, skin, and several hormone-producing (endocrine) tissues.
People with McCune-Albright syndrome develop areas of abnormal scar-like (fibrous) tissue in their bones, a condition called polyostotic fibrous dysplasia. Polyostotic means the abnormal areas (lesions) may occur in many bones; often they are confined to one side of the body. Replacement of bone with fibrous tissue may lead to fractures, uneven growth, and deformity. When lesions occur in the bones of the skull and jaw it can result in uneven (asymmetric) growth of the face. Asymmetry may also occur in the long bones; uneven growth of leg bones may cause limping. Abnormal curvature of the spine (scoliosis) may also occur. Bone lesions may become cancerous, but this happens in fewer than 1 percent of people with McCune-Albright syndrome.
In addition to bone abnormalities, affected individuals usually have light brown patches of skin called café-au-lait spots, which may be present from birth. The irregular borders of the café-au-lait spots in McCune-Albright syndrome are often compared to a map of the coast of Maine. By contrast, café-au-lait spots in other disorders have smooth borders, which are compared to the coast of California. Like the bone lesions, the café-au-lait spots in McCune-Albright syndrome may appear on only one side of the body.
Girls with McCune-Albright syndrome may reach puberty early. These girls often have menstrual bleeding by age 2. This early onset of menstruation is believed to be caused by excess estrogen, a female sex hormone, produced by cysts that develop in one of the ovaries. Less commonly, boys with McCune-Albright syndrome may also experience early puberty.
Other endocrine problems may also occur in people with McCune-Albright syndrome. The thyroid gland, a butterfly-shaped organ at the base of the neck, may become enlarged (a condition called a goiter) or develop masses called nodules. About 50 percent of affected individuals produce excessive amounts of thyroid hormone (hyperthyroidism), resulting in a fast heart rate, high blood pressure, weight loss, tremors, sweating, and other symptoms. The pituitary gland (a structure at the base of the brain that makes several hormones) may produce too much growth hormone. Excess growth hormone can result in acromegaly, a condition characterized by large hands and feet, arthritis, and distinctive facial features that are often described as "coarse." Excess growth hormone secretion may also lead to increased expansion of the fibrous dysplasia in the bones, most visibly in the skull. Rarely, affected individuals develop Cushing syndrome, an excess of the hormone cortisol produced by the adrenal glands, which are small glands located on top of each kidney. Cushing syndrome causes weight gain in the face and upper body, slowed growth in children, fragile skin, fatigue, and other health problems. In people with McCune-Albright syndrome, Cushing syndrome occurs only before age 2.
Problems in other organs and systems, such as noncancerous (benign) gastrointestinal growths called polyps and other abnormalities, can also occur in McCune-Albright syndrome.
Causes and biological mechanisms
From: MedlinePlus Genetics, National Library of Medicine
McCune-Albright syndrome is caused by a mutation in the GNAS gene. The GNAS gene provides instructions for making one part of a protein complex called a guanine nucleotide-binding protein, or a G protein.
In a process called signal transduction, G proteins trigger a complex network of signaling pathways that ultimately influence many cell functions by regulating the activity of hormones. The protein produced from the GNAS gene helps stimulate the activity of an enzyme called adenylate cyclase. GNAS gene mutations that cause McCune-Albright syndrome result in a G protein that causes the adenylate cyclase enzyme to be constantly turned on (constitutively activated). Constitutive activation of the adenylate cyclase enzyme leads to over-production of several hormones, resulting in abnormal bone growth and other signs and symptoms of McCune-Albright syndrome.
Inheritance and family implications
From: MedlinePlus Genetics, National Library of Medicine
McCune-Albright syndrome is not inherited. Instead, it is caused by a random mutation in the GNAS gene that occurs very early in development. As a result, some of the body's cells have a normal version of the GNAS gene, while other cells have the mutated version. This phenomenon is called mosaicism. The severity of this disorder and its specific features depend on the number and location of cells that have the mutated GNAS gene. Affected individuals may have reproductive cells (eggs or sperm) with the mutation. However, a resulting embryo would have the mutation in every cell, which is thought to be incompatible with life, so the condition is not passed to the next generation.
How common is it?
From: MedlinePlus Genetics, National Library of Medicine
McCune-Albright syndrome occurs in 1 in 100,000 to 1 in 1,000,000 people worldwide.
Reported clinical features and what the terms mean
The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.
The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.
- Abnormal endocrine physiology · Very frequent (99-80%)
- Any anomaly of the function of the endocrine system.
- Large cafe-au-lait macules with irregular margins · Very frequent (99-80%)
- Large hypermelanotic macules with jagged borders.
- Ovarian cyst · Very frequent (99-80%)
- The presence of one or more cysts of the ovary.
- Precocious puberty · Very frequent (99-80%)
- The onset of secondary sexual characteristics before a normal age. Although it is difficult to define normal age ranges because of the marked variation with which puberty begins in normal children, precocious puberty can be defined as the onset of puberty before the age of 8 years in girls or 9 years in boys.
- Abnormal testis morphology · Frequent (79-30%)
- An anomaly of the testicle (the male gonad).
- Abnormality of facial skeleton · Frequent (79-30%)
- An abnormality of one or more of the set of bones that make up the facial skeleton.
- Abnormality of femur morphology · Frequent (79-30%)
- Any anomaly of the structure of the femur.
- Abnormality of the skull base · Frequent (79-30%)
- An abnormality of the base of the skull, which forms the floor of the cranial cavity and separates the brain from other facial structures. The skull base is made up of five bones: the ethmoid, sphenoid, occipital, paired frontal, and paired parietal bones, and is subdivided into 3 regions: the anterior, middle, and posterior cranial fossae. The petro-occipital fissure subdivides the middle cranial fossa into 1 central component and 2 lateral components.
Other findings in the same source
From: Orphanet
Additional reported features include Abnormality of the thyroid gland (Frequent (79-30%)); Accelerated skeletal maturation (Frequent (79-30%)); Fibrous dysplasia of the bones (Frequent (79-30%)); Hyperthyroidism (Frequent (79-30%)); Increased serum testosterone level (Frequent (79-30%)); Macroorchidism (Frequent (79-30%)); Monostotic fibrous dysplasia (Frequent (79-30%)); Renal tubular dysfunction (Frequent (79-30%)); Scoliosis (Frequent (79-30%)); Growth abnormality (Frequent (79-30%)). This is a selected summary, not a complete description of the condition.
Which doctor should you see?
The suggested department for discussing McCune-Albright syndrome is Orthopaedics, with a orthopaedic specialist as the relevant type of clinician. General physician / Family Medicine; paediatrician for children. Referral depends on symptoms.
Additional services that may be relevant, depending on the findings, include: Clinical Genetics.
This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.
How to prepare for an assessment
Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.
Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.
- What explains the change in pain, movement or function?
- Which activities need adjustment while the diagnosis is being clarified?
- What are the roles of rehabilitation, observation and surgery in this situation?
Treatment discussions and follow-up
The material gathered for this draft does not provide a complete condition-specific treatment pathway for McCune-Albright syndrome. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.
Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.
The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.
When to seek emergency help
Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.
This condition is usually assessed by an orthopaedic surgeon. Every profile shows the doctor’s registration and what has been checked.
Sources
- MedlinePlus Genetics, National Library of Medicine — McCune-Albright syndrome — Public-domain Genetics summary
- Orphanet — clinical features for ORPHA:562 — Orphadata Science, CC BY 4.0
- Human Phenotype Ontology Consortium — terminology definitions — HPO licence; definitions reproduced without alteration
- Government of India — Emergency Response Support System — Official reference for India emergency number
Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.
General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-1497.